Investigation Initiated by Pomerantz LLP for Sangamo Therapeutics Investors

Pomerantz Law Firm Investigates Sangamo Therapeutics

Pomerantz LLP, a leading law firm recognized for its expertise in corporate law and securities litigation, is currently investigating claims on behalf of investors of Sangamo Therapeutics, Inc., a company listed on NASDAQ under the ticker SGMO. This investigation arises from significant concerns regarding potential securities fraud and other unlawful business practices allegedly committed by Sangamo and some of its management team.

Background on the Investigation

In recent months, Sangamo has faced notable scrutiny following a public announcement related to their partnership with pharmaceutical giant Pfizer. On December 30, 2024, during after-market hours, Sangamo revealed that Pfizer, which was co-developing a gene therapy candidate for hemophilia A named giroctocogene fitelparvovec, would be returning its rights to Sangamo. Pfizer made this decision despite this candidate being in phase 3 of trials, a crucial stage often expected to lead to forthcoming submissions for regulatory approvals.

Sangamo expressed substantial disappointment in Pfizer's decision, indicating that it had anticipated progressing towards Biologics License Application and Marketing Authorization Application submissions by early 2025. However, the abrupt end to this collaboration took many stakeholders by surprise, leading to notable fluctuations in Sangamo's stock price. On December 31, 2024, following this announcement, the company experienced a drastic decline in stock value during trading hours.

PFizer’s withdrawal marks a significant setback for Sangamo, especially with the effective termination of their collaboration set for April 21, 2025. This will require Pfizer to transition the entire giroctocogene fitelparvovec program back to Sangamo, potentially complicating the company's future plans and affecting investor sentiments.

Call to Action for Investors

Pomerantz LLP encourages investors who have suffered losses as a result of this situation to reach out to them. Specifically, they are advising those who feel affected by the company's actions—or inactions—to get in contact with attorney Danielle Peyton. She can be reached at 646-581-9980, or via email for further assistance and to discuss potential participation in a class action lawsuit.

The firm has a longstanding history in championing the rights of shareholders, successfully dealing with cases related to corporate misconduct and securities fraud for over 85 years. Founded by the late Abraham L. Pomerantz, the firm is renowned for its pioneering work in the field of securities class actions.

Conclusion

As the investigation unfolds, it will undoubtedly attract attention from both current shareholders and potential investors in Sangamo. The outcome of this investigation may reveal significant insights into the company's operational integrity and transparency practices, as well as affect the future trajectory of Sangamo Therapeutics.

For ongoing updates regarding this case and other related developments, interested parties should remain vigilant and monitor news releases from Pomerantz LLP. This situation serves as a critical reminder of the inherent risks involved in investing, particularly in the pharmaceutical sector where partnerships can dramatically impact stock performance.